Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2023-12-11 09:09 am Sale |
2023-12-08 | 13G | Evelo Biosciences, Inc. EVLO |
FMR CORP | 0 0.000% |
-1,326,267 (Position Closed) |
Filing History |
| 2023-11-13 09:02 am Sale |
2023-11-10 | 13G | Evelo Biosciences, Inc. EVLO |
FMR CORP | 1,326,267 7.041% |
-1,125,985 (-45.92%) |
Filing History |
| 2023-08-10 08:19 am Purchase |
2023-08-09 | 13G | Evelo Biosciences, Inc. EVLO |
FMR CORP | 2,452,252 14.750% |
2,325,827 (+1839.69%) |
Filing History |
| 2023-07-21 3:46 pm Purchase |
2023-07-11 | 13G | Evelo Biosciences, Inc. EVLO |
Horizon Technology Finance Corp HRZN |
2,164,502 11.500% |
2,164,502 (New Position) |
Filing History |
| 2023-07-21 08:00 am Purchase |
2023-07-11 | 13G | Evelo Biosciences, Inc. EVLO |
HarbourVest Partners L.P. | 1,451,876 8.800% |
1,451,876 (New Position) |
Filing History |
| 2023-07-13 5:00 pm Purchase |
2023-07-11 | 13D | Evelo Biosciences, Inc. EVLO |
Flagship Ventures Fund V, L.P. | 7,932,624 42.200% |
7,932,624 (New Position) |
Filing History |
| 2023-07-10 10:20 am Purchase |
2023-07-07 | 13G | Evelo Biosciences, Inc. EVLO |
FMR CORP | 126,425 2.257% |
126,425 (New Position) |
Filing History |
| 2023-06-12 08:21 am Sale |
2023-06-09 | 13G | Evelo Biosciences, Inc. EVLO |
FMR CORP | 489,782 8.746% |
-331,635 (-40.37%) |
Filing History |
| 2023-02-21 06:10 am Purchase |
2023-02-21 | 13D | Evelo Biosciences, Inc. EVLO |
DNCA FINANCE | 22 4.960% |
22 (New Position) |
Filing History |
| 2023-02-14 06:10 am Unchanged |
2022-12-31 | 13G | Evelo Biosciences, Inc. EVLO |
HarbourVest Partners L.P. | 153,175 2.800% |
0 (Unchanged) |
Filing History |
| 2023-02-09 10:59 am Purchase |
2023-02-09 | 13G | Evelo Biosciences, Inc. EVLO |
FMR CORP | 821,418 14.987% |
420,468 (+104.87%) |
Filing History |
| 2023-02-02 1:43 pm Purchase |
2022-12-31 | 13G | Evelo Biosciences, Inc. EVLO |
CREDIT SUISSE FIRST BOSTON | 183,919 3.350% |
5,595 (+3.14%) |
Filing History |
| 2022-11-21 08:28 am Sale |
2022-11-21 | 13D | Evelo Biosciences, Inc. EVLO |
DNCA FINANCE | 0 0.000% |
-46 (Position Closed) |
Filing History |
| 2022-08-23 09:32 am Purchase |
2022-08-23 | 13D | Evelo Biosciences, Inc. EVLO |
DNCA FINANCE | 46 3.630% |
12 (+33.72%) |
Filing History |
| 2022-06-01 5:01 pm Purchase |
2022-05-27 | 13D | Evelo Biosciences, Inc. EVLO |
Flagship Ventures Fund V, L.P. | 2,521,366 46.700% |
1,369,863 (+118.96%) |
Filing History |
| 2022-02-14 1:25 pm Purchase |
2021-12-31 | 13G | Evelo Biosciences, Inc. EVLO |
CREDIT SUISSE FIRST BOSTON | 178,324 6.670% |
43,049 (+31.82%) |
Filing History |
| 2022-02-09 09:11 am Purchase |
2022-02-08 | 13G | Evelo Biosciences, Inc. EVLO |
FMR CORP | 400,950 14.999% |
60,781 (+17.87%) |
Filing History |
| 2021-12-28 3:58 pm Purchase |
2021-12-28 | 13D | Evelo Biosciences, Inc. EVLO |
DNCA FINANCE | 34 5.030% |
34 (New Position) |
Filing History |
| 2021-02-16 07:59 am Purchase |
2020-12-31 | 13G | Evelo Biosciences, Inc. EVLO |
HarbourVest Partners L.P. | 153,175 6.600% |
65,000 (+73.72%) |
Filing History |
| 2021-02-12 4:16 pm Purchase |
2020-12-31 | 13G | Evelo Biosciences, Inc. EVLO |
CREDIT SUISSE FIRST BOSTON | 135,276 5.860% |
135,276 (New Position) |
Filing History |